Nutriband (NTRB) announced that through its 4P Therapeutics subsidiary, it has signed an agreement with Brand Institute to develop the worldwide commercial brand name and visual identity for its lead product, an abuse deterrent fentanyl transdermal system. This product utilizes Nutriband’s AVERSA abuse deterrent transdermal technology and has the development name AVERSA FENTANYL.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRB:
- Nutriband files provisional patent application for AVERSA technology
- Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
- Nutriband reports Q2 EPS ($2.12) vs. (15c) last year
- Nutriband Issues Shares Amid Investor Engagement
- Nutriband CEO Gareth Sheridan steps aside for Irish election